Related Experiment Video
Updated: Feb 3, 2026
Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Molecular Characterization of Bladder Cancer
Thenappan Chandrasekar1,2, Annette Erlich3,4, Alexandre R Zlotta5,6,7
1Department of Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University of Toronto and University Health Network, Toronto, ON, Canada.
Purpose Of Review:
Bladder cancer (BCa) management had remained unchanged for 20+ years with clinicians, in contrast to many other cancer types, rarely relying on molecular characteristics to guide management. The past 5 years have yielded significant advances in our knowledge of the molecular basis of BCa and concurrent advances in systemic therapy. We aim to highlight the key developments and potential future direction of BCa management.
Recent Findings:
Next-generation sequencing (NGS) has drastically altered the understanding of muscle-invasive BCa (MIBC) and non-muscle invasive BCa (NMIBC). MIBC molecular subtyping efforts from several groups worldwide grouped into an international consortium into five classes, broadly grouped into basal and luminal subtypes, have attempted to improve prediction of clinical outcomes and treatment response, either chemotherapy or immunotherapy. NMIBC molecular subtyping is yielding similar disease stratification, superior to histopathology alone. Additionally, with new actionable targets being identified for patients non-responsive to traditional therapy, ongoing and upcoming clinical trials are increasingly emphasizing the importance of the molecular testing. The molecular characterization of bladder cancer is rapidly progressing and will likely alter treatment paradigms in the near future.
Insights
Molecular insights are revolutionizing bladder cancer (BCa) management. Next-generation sequencing (NGS) enables precise BCa subtyping, improving treatment prediction and identifying new therapeutic targets.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Bladder cancer (BCa) management has seen limited evolution over two decades.
- Clinicians traditionally overlook molecular characteristics in BCa treatment decisions.
- Recent breakthroughs in molecular understanding and systemic therapies are transforming BCa care.
Purpose of the Study:
- To review key developments in bladder cancer molecular profiling.
- To discuss the impact of molecular advances on BCa management.
- To explore future directions in BCa treatment guided by molecular data.
Main Methods:
- Utilizing next-generation sequencing (NGS) for molecular subtyping of bladder cancer.
- Analyzing international consortium data for muscle-invasive BCa (MIBC) classification.
- Evaluating molecular stratification for non-muscle invasive BCa (NMIBC).
Main Results:
- NGS has significantly advanced the understanding of MIBC and NMIBC.
- MIBC molecular subtyping identified five classes, aiding treatment response prediction.
- NMIBC molecular subtyping offers superior stratification compared to histopathology alone.
- New actionable targets are emerging for refractory BCa cases.
Conclusions:
- Molecular characterization is rapidly advancing bladder cancer understanding.
- Emerging molecular data is poised to alter current treatment paradigms.
- Future BCa management will increasingly integrate molecular testing for personalized therapy.
Related Concept Videos
01:23Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
02:00Molecular Models
03:51Molecular Orbital Theory II
02:35Molecular Orbital Theory I
02:27Predicting Molecular Geometry
01:19Anatomy of the Genitourinary System II: Bladder and Urethra